CSPC Pharmaceutical Group (HK:1093) has released an update.
CSPC Innovation Pharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group, reported a significant decline in its financial performance for the nine months ending September 2024. Revenue fell by 23.66% while net profit attributable to shareholders plummeted by 63.50% compared to the previous year. Investors are advised to exercise caution when dealing with the company’s securities amidst these challenging financial results.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
